Regulated Information
Ipsen announces U.S. FDA Priority Review for palovarotene New Drug Application in patients with fibrodysplasia ossificans progressiva following resubmission
Ipsen announces the launch of an Employee Shareholding Plan
Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – June 2024 – Monthly information relative to the...
Half-year statement of IPSEN liquidity agreement – 2024 06 30
Ipsen expands collaboration and license agreement for development of Cabometyx®...
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class...
You are now leaving the Ipsen group global website. To continue, please click on Continue?
How easy was it to navigate Ipsen website and locate the information you were seeking?
